Announcements Trials
Browse Landscape

Phase

Phase 1 39Phase 2 31Phase 1/2 6Phase 3 3Phase EARLY_PHASE1 2Phase 2/3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Head & Neck 1

Conditions

Neoplasm Metastasis 2Breast Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 361Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Interventional × NVP-BKM120 × Clear all
NCT04338399 2025-11-17

BURAN

Adlai Nortye Biopharma Co., Ltd.

Phase 3 Completed
487 enrolled
Head & Neck

Head and Neck Neoplasms

NCT01610284 2020-08-25

BELLE-2

Novartis

Phase 3 Completed
1,147 enrolled 20 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01633060 2019-01-30

BELLE-3

Novartis

Phase 3 Terminated
432 enrolled 20 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡